[1]
Bodeker G,
Kronenberg F. A public health agenda for traditional, complementary, and alternative medicine. Am J Public Health 2002; 92(10): 1582-91.
[2]
Morris CA,
Avorn J. Internet marketing of herbal products. JAMA 2003; 290(11): 1505-9.
[3] Al-Safi SA, Ayoub NM, Ayoub AM, Al-Momany E, Al-Doghim I, Al-Balas M, Alkofahi AS, Aboul-Enein FH, Aboul-Enein BH. Public awareness of the abuse of herbs and drugs to decrease body weight: a novel national survey in Jordan. J Public Health 2008; 16: 205-13.
[4]
Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 2002; 252(2): 107-13.
[5]
de Carvalho LM,
Martini M,
Moreira AP,
de Lima AP,
Correia D,
Falcão T,
Garcia SC,
de Bairros AV,
do Nascimento PC,
Bohrer D. Presence of synthetic pharmaceuticals as adulterants in slimming phytotherapeutic formulations and their analytical determination.
Forensic Sci Int 2011; 204(1-3): 6-12.
[6]
Deng JF. Clinical and laboratory investigations in herbal poisonings.
Toxicology 2002; 181-182: 571-6.
[7]
Bogusz MJ,
Hassan H,
Al-Enazi E,
Ibrahim Z,
Al-Tufail M. Application of LC-ESI-MS-MS for detection of synthetic adulterants in herbal remedies.
J Pharm Biomed Anal 2006; 41(2): 554-64.
[8] Pharmaceuticals: Restrictions in use and availability. Essential Drugs and Medicines- Quality Assurance and Safety of Medicines, Health Technology and Pharmaceuticals, World Health Organization, 2001; Available at: http://archives.who.int/tbs/qual/s2203e.pdf
[9]
Calapai G. European legislation on herbal medicines: a look into the future.
Drug Saf 2008; 31(5): 428-31.
[10] WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. World Health Organisation, 2004; Available at: http://apps.who.int/medicinedocs/documents/s7148e/s7148e.pdf
[11]
Hoggan AM,
Shelby MK,
Crouch DJ,
Borges CR,
Slawson MH. Detection of bumetanide in an over-the-counter dietary supplement.
J Anal Toxicol 2007; 31(9): 601-4.
[12] Venhuis BJ, Zwaagstra ME, van den Berg JDJ, Wagenaar HWG, van Riel AJHP , Barends DM, Kaste D. Trends in drug substances detected in illegal weight-loss medicines and dietary supplements. A 2002-2007 survey and health risk analysis. RIVM Report 370030002, 2009; Available at: http://vorige.nrc.nl/multimedia/dynamic/00213/370030002_213599a.pdf
[13] Anti-obesity drugs. Guidance on appropriate prescribing and management. A report of the Nutrition Committee of the Royal College of Physicians of London. 2003; Available at: http://www.rcplondon.ac.uk/sites/default/files/documents/anti-obesity_reportweb.pdf
[14]
Nazeri A,
Massumi A,
Wilson JM,
Frank CM,
Bensler M,
Cheng J,
Saeed M,
Rasekh A,
Razavi M. Arrhythmogenicity of weight-loss supplements marketed on the Internet.
Heart Rhythm 2009; 6(5): 658-62.
[15] Khazan M, Hedayati M, Askari S, Azizi F. Adulteration of products sold as Chinese Herbal medicines for weight loss with thyroid hormones and PCP. Journal of Herbal Medicine 2013; 3(1): 39-43.
[16]
Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents).
Braz J Med Biol Res 2000; 33(2): 179-89.
[17]
Yuen YP,
Lai CK,
Poon WT,
Ng SW,
Chan AY,
Mak TW. Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat.
Hong Kong Med J 2007; 13(3): 216-20.
[18]
Cordeiro Q,
Vallada H. Sibutramine-induced mania episode in a bipolar patient.
Int J Neuropsychopharmacol 2002; 5(3): 283-4.
[19]
Taflinski T,
Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000; 157(12): 2057-8.
[20]
Zou P,
Oh SS,
Kiang KH,
Low MY,
Bloodworth BC. Detection of sibutramine, its two metabolites and one analogue in a herbal product for weight loss by liquid chromatography triple quadrupole mass spectrometry and time-of-flight mass spectrometry.
Rapid Commun Mass Spectrom 2007; 21(4): 614-8.
[21]
Luque CA,
Rey JA. The discovery and status of sibutramine as an anti-obesity drug.
Eur J Pharmacol 2002; 440(2-3): 119-28.
[22]
Jung J,
Hermanns-Clausen M,
Weinmann W. Anorectic sibutramine detected in a Chinese herbal drug for weight loss.
Forensic Sci Int 2006; 161(2-3): 221-2.
[23]
Graham I,
Atar D,
Borch-Johnsen K,
Boysen G,
Burell G,
Cifkova R,
Dallongeville J,
De Backer G,
Ebrahim S,
Gjelsvik B,
Herrmann-Lingen C,
Hoes A,
Humphries S,
Knapton M,
Perk J,
Priori SG,
Pyorala K,
Reiner Z,
Ruilope L,
Sans-Menendez S,
Op Reimer WS,
Weissberg P,
Wood D,
Yarnell J,
Zamorano JL,
Walma E,
Fitzgerald T,
Cooney MT,
Dudina A,
Vahanian A,
Camm J,
De Caterina R,
Dean V,
Dickstein K,
Funck-Brentano C,
Filippatos G,
Hellemans I,
Kristensen SD,
McGregor K,
Sechtem U,
Silber S,
Tendera M,
Widimsky P,
Zamorano JL,
Altiner A,
Bonora E,
Durrington PN,
Fagard R,
Giampaoli S,
Hemingway H,
Hakansson J,
Kjeldsen SE,
Larsen ML,
Mancia G,
Manolis AJ,
Orth-Gomer K,
Pedersen T,
Rayner M,
Ryden L,
Sammut M,
Schneiderman N,
Stalenhoef AF,
Tokgözoglu L,
Wiklund O,
Zampelas A;
European Society of Cardiology (ESC);
European Association for Cardiovascular Prevention and Rehabilitation (EACPR);
Council on Cardiovascular Nursing;
European Association for Study of Diabetes (EASD);
International Diabetes Federation Europe (IDF-Europe);
European Stroke Initiative (EUSI);
International Society of Behavioural Medicine (ISBM);
European Society of Hypertension (ESH);
European Society of General Practice/Family Medicine (ESGP/FM/WONCA);
European Heart Network (EHN). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2: E1-40.
[24]
Nisoli E,
Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
Obes Rev 2000; 1(2): 127-39.
[25]
Luque CA,
Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
Ann Pharmacother 1999; 33(9): 968-78.
[26]
Coogan PF,
Rosenberg L,
Palmer JR,
Strom BL,
Zauber AG,
Stolley PD,
Shapiro S. Phenolphthalein laxatives and risk of cancer.
J Natl Cancer Inst 2000; 92(23): 1943-4.
[27]
Martin M,
Schlabach G,
Shibinski K. The Use of Nonprescription Weight Loss Products Among Female Basketball, Softball, and Volleyball Athletes from NCAA Division I Institutions: Issues and Concerns.
J Athl Train 1998; 33(1): 41-4.
[28]
Zaacks SM,
Klein L,
Tan CD,
Rodriguez ER,
Leikin JB. Hypersensitivity myocarditis associated with ephedra use.
J Toxicol Clin Toxicol 1999; 37(4): 485-9.
[29]
Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J
Clin Psychopharmacol 1997; 17(5): 437-9.
[30]
Haller CA,
Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.
N Engl J Med 2000; 343(25): 1833-8.
[31]
Holmgren P,
Nordén-Pettersson L,
Ahlner J. Caffeine fatalities--four case reports. Forensic Sci Int 2004; 139(1): 71-3.
[32]
Cannon ME,
Cooke CT,
McCarthy JS. Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.
Med J Aust 2001; 174(10): 520-1.
[33]
Gomez MR,
Cerutti S,
Sombra LL,
Silva MF,
Martínez LD. Determination of heavy metals for the quality control in Argentinian herbal medicines by ETAAS and ICP-OES.
Food Chem Toxicol 2007; 45(6): 1060-4
[34]
Chan K. Some aspects of toxic contaminants in herbal medicines.
Chemosphere 2003; 52(9): 1361-71.
[35]
Little JD,
Romans SE. Psychosis following readministration of diethyl proprion: a possible role for kindling?
Int Clin Psychopharmacol 1993; 8(1): 67-70.
Pathobiology Reserach